Maastricht University Medical Centre
Maastricht, 6202 AZ, Netherlands
NCT Number: NCT00626938
Sarcoidosis is a multi-systemic disorder, meaning that it can involve any organ in the body and that its clinical presentation is highly variable. In 90% of all sarcoidosis cases the lungs are affected. It is difficult to give a concise definition of sarcoidosis due to the fact that its exact cause is still unknown. Consequently, diagnosing the disease is also rather difficult. Up till now, sarcoidosis is generally diagnosed by using general clinical methods to evaluate the status of the lung including a chest X-ray, lung biopsy and bronchoalveolar lavage (BAL). However, some of these methods are considered to be rather invasive and, even more important, non-conclusive. Therefore, the current study has been designed to evaluate the use of a new technique, called SELDI-TOF mass spectrophotometry, for the diagnosis of sarcoidosis. This technique enables the analysis of all enzymes present in the blood of sarcoidosis patients which may hopefully lead to creating a disease-specific protein-profile that may facilitate the recognition of sarcoidosis. Moreover, these results will be compared with other currently used laboratory parameters.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Maastricht, 6202 AZ, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: within 1 month after obtaining sample
Time frame: within 6 months after obtaining sample
Maastricht University Medical Center
Other
Proteomics as a Tool for Biomarker Detection in Sarcoidosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03814317
Cardiovascular Diseases, Hemic and Lymphatic Diseases
Gainesville, Florida, United States
View Trial DetailsNCT01610843
Hemic and Lymphatic Diseases, Hypersensitivity
Iowa City, Iowa, United States
View Trial DetailsNCT01687517
Hemic and Lymphatic Diseases, Hypersensitivity
Paris, France
View Trial DetailsNCT06907953
COVID-19, Chronic Disease
New York, United States
View Trial Details